Trending Topic

23 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Luke G Qin, Michael T Pierce, Rachel C Robbins

The uvea is a vascular stratum that includes the iris, ciliary body and choroid. Uveitis is defined as inflammation of a part of the uvea or its entirety, but it is also used to describe inflammatory processes of any part of the eye, such as the vitreous or peripheral retina. The clinical taxonomy of uveitis […]

Arshad Khanani, ARVO 2022: RGX-314 gene therapy for neovascular age-related macular degeneration

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 27th 2022

An overview and the mechanism of action of RGX-314 is discussed in this touchOPHTHALMOLOGY interview with Prof. Arshad Khanani (Sierra Eye Associates, Reno, NV, USA) as well as the limitations of anti-VEGF therapy for neovascular AMD.

The presentation entitled ‘Suprachoroidal Delivery of RGX-314 Gene Therapy for Neovascular AMD: The Phase II AAVIATE™ Study’ was presented at the The Association for Research in Vision and Ophthalmology, May 01-04, 2022.

Questions:

  1. What are the limitations of anti-VEGF therapy for neovascular AMD?
  2. What is RGX-314 and what is its mechanism of action?

Disclosures: Arshad Khanani is a consultant for Regenxbio and discloses grant/research Support from Regenxbio.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup